Compare PLPC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLPC | URGN |
|---|---|---|
| Founded | 1947 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2001 | 2016 |
| Metric | PLPC | URGN |
|---|---|---|
| Price | $384.27 | $33.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $275.00 | $29.29 |
| AVG Volume (30 Days) | 87.8K | ★ 560.1K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $17.19 | $129.09 |
| Revenue Next Year | $7.28 | $70.96 |
| P/E Ratio | $179.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $139.04 | $12.73 |
| 52 Week High | $397.34 | $33.79 |
| Indicator | PLPC | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 73.21 |
| Support Level | $193.52 | $18.58 |
| Resistance Level | $397.34 | N/A |
| Average True Range (ATR) | 19.63 | 1.67 |
| MACD | -1.21 | 0.45 |
| Stochastic Oscillator | 72.69 | 97.18 |
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. The Company's primary products support, protect, connect, terminate, and secure cables and wires. The Company provides helical solutions, connectors, fiber optic and copper splice closures, solar framing applications, and electric vehicle charging station foundations. The Company's customers include public and private energy utilities and communication companies, cable operators, contractors and subcontractors, distributors, and value-added resellers. Geographically, the company operates in four regions: PLP-USA, the Americas, EMEA, and Asia-Pacific.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.